Therefore, PD-1 inhibitors are expected to become the new standard of care for patients with locally advanced and metastatic cSCC.52, 53, 54, 55 However, patients not eligible for anti-PD-1 treatment, e.g., organ transplant recipients or patients refractory to anti-PD-1 therapy, may be offered EGFR inhibitors and/or chemotherapy.52 Here, EGFR is linked to skin squamous cell carcinoma.